SCHEMBL717000

SCHEMBL717000

CC(C)(C(N)=O)[C@@H]1CCCN1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 2/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
KDM4E B2RXH2 2/20 0.36
CYP2D6 P10635 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
GLI1 P08151 1/20 0.34
MEN1 O00255 1/20 0.34
BLM P54132 1/20 0.34
DPP4 P27487 2/20 0.30
FAP Q12884 1/20 0.30
DPP8 Q6V1X1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717921 1.00 NOS2 (0.36) NOS2NOS3NOS1KDM4ECYP2D6
SCHEMBL15995652 1.00 NOS2 (0.36) NOS2NOS3NOS1KDM4ECYP2D6
SCHEMBL8283621 0.94 CCR2 (0.33) NOS2NOS3NOS1KDM4ECYP2D6
SCHEMBL8471413 0.94 CCR2 (0.33) NOS2NOS3NOS1KDM4ECYP2D6
Hydrochloric Acid SCHEMBL9698143 0.92 KDM4E (0.34) NOS2NOS3NOS1KDM4ECYP2D6
SCHEMBL3661210 0.82 KDM4E (0.41) KDM4ECYP2D6NPC1CYP1A2HPGD
SCHEMBL6599580 0.77 KDM4E (0.34) KDM4ECYP2D6NPC1CYP1A2HPGD
SCHEMBL19819319 0.76 KDM4E (0.36) KDM4ECYP2D6NPC1CYP1A2HPGD
SCHEMBL12928750 0.76 SLC6A2 (0.35) KDM4ECYP2D6NPC1CYP1A2HPGD
SCHEMBL12928728 0.76 SLC6A2 (0.35) KDM4ECYP2D6NPC1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067951-B2 Process and intermediates for the production of CCR2 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-06-30 US disclosed
US-20140336374-A1 PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-13 US disclosed
US-20120053164-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053164-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD CCR2, CCR1, CCR5 NOS2 558/4885NOS3 818/4885NOS1 941/4885
US-20140336374-A1 PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS CCR2, CCR5, CCR1 NOS2 1185/4885NOS3 2100/4885NOS1 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.